CD19‐Targeted chimeric antigen receptor‐modified T‐cell immunotherapy for B‐cell malignancies
Authors:
- 12 May 2016
- journal article
- research article
- Published by Wiley in Clinical Pharmacology & Therapeutics
- Vol. 100 (3) , 252-258
Abstract
Chimeric antigen receptors (CARs) comprise a tumor‐targeting moiety, often in the form of a single chain variable fragment derived from a monoclonal antibody, fused to one or more intracellular T‐cell signaling sequences. Lymphodepletion chemotherapy followed by infusion of T cells that are genetically modified to express a CD19‐specific CAR is a promising therapy for patients with refractory CD19+ B‐cell malignancies, producing rates of complete remission that are remarkably high in acute lymphoblastic leukemia and encouraging in non‐Hodgkin lymphoma and chronic lymphocytic leukemia. Responses are often durable, although additional studies are needed to define the role of CAR‐T cell immunotherapy in the context of other treatments. CAR‐modified T‐cell immunotherapy can be complicated by cytokine release syndrome and neurologic toxicity, which in most cases are manageable and reversible. Here we review recent clinical trial data and discuss issues for the field.Keywords
This publication has 43 references indexed in Scilit:
- Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemiaScience Translational Medicine, 2015
- T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trialThe Lancet, 2015
- Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 studyThe Lancet Oncology, 2015
- Chimeric Antigen Receptor T Cells for Sustained Remissions in LeukemiaNew England Journal of Medicine, 2014
- Current concepts in the diagnosis and management of cytokine release syndromeBlood, 2014
- Efficacy and Toxicity Management of 19-28z CAR T Cell Therapy in B Cell Acute Lymphoblastic LeukemiaScience Translational Medicine, 2014
- Chimeric antigen receptor modified T cell therapy for B cell malignanciesInternational Journal of Hematology, 2013
- B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor–transduced T cellsBlood, 2012
- CD28 costimulation improves expansion and persistence of chimeric antigen receptor–modified T cells in lymphoma patientsJournal of Clinical Investigation, 2011
- CD19, the earliest differentiation antigen of the B cell lineage, bears three extracellular immunoglobulin-like domains and an Epstein-Barr virus-related cytoplasmic tail.Journal of Experimental Medicine, 1988